Last reviewed · How we verify
Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer
The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.
Details
| Lead sponsor | Astellas Pharma Inc |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 47 |
| Start date | 2002-09 |
| Completion | 2003-02 |
Conditions
- SCLC
- Carcinoma, Small Cell
Interventions
- OSI-211 (Liposomal Lurtotecan)
Countries
United States, United Kingdom